Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group - PubMed (original) (raw)
Meta-Analysis
. 1998 Sep 19;352(9132):930-42.
- PMID: 9752815
Meta-Analysis
Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group
No authors listed. Lancet. 1998.
Abstract
Background: There have been many randomised trials of adjuvant prolonged polychemotherapy among women with early breast cancer, and an updated overview of their results is presented.
Methods: In 1995, information was sought on each woman in any randomised trial that began before 1990 and involved treatment groups that differed only with respect to the chemotherapy regimens that were being compared. Analyses involved about 18,000 women in 47 trials of prolonged polychemotherapy versus no chemotherapy, about 6000 in 11 trials of longer versus shorter polychemotherapy, and about 6000 in 11 trials of anthracycline-containing regimens versus CMF (cyclophosphamide, methotrexate, and fluorouracil).
Findings: For recurrence, polychemotherapy produced substantial and highly significant proportional reductions both among women aged under 50 at randomisation (35% [SD 4] reduction; 2p<0.00001) and among those aged 50-69 (20% [SD 3] reduction; 2p<0.00001); few women aged 70 or over had been studied. For mortality, the reductions were also significant both among women aged under 50 (27% [SD 5] reduction; 2p<0.00001) and among those aged 50-69 (11% [SD 3] reduction; 2p=0.0001). The recurrence reductions emerged chiefly during the first 5 years of follow-up, whereas the difference in survival grew throughout the first 10 years. After standardisation for age and time since randomisation, the proportional reductions in risk were similar for women with node-negative and node-positive disease. Applying the proportional mortality reduction observed in all women aged under 50 at randomisation would typically change a 10-year survival of 71% for those with node-negative disease to 78% (an absolute benefit of 7%), and of 42% for those with node-positive disease to 53% (an absolute benefit of 11%). The smaller proportional mortality reduction observed in all women aged 50-69 at randomisation would translate into smaller absolute benefits, changing a 10-year survival of 67% for those with node-negative disease to 69% (an absolute gain of 2%) and of 46% for those with node-positive disease to 49% (an absolute gain of 3%). The age-specific benefits of polychemotherapy appeared to be largely irrespective of menopausal status at presentation, oestrogen receptor status of the primary tumour, and of whether adjuvant tamoxifen had been given. In terms of other outcomes, there was a reduction of about one-fifth (2p=0.05) in contralateral breast cancer, which has already been included in the analyses of recurrence, and no apparent adverse effect on deaths from causes other than breast cancer (death rate ratio 0.89 [SD 0.09]). The directly randomised comparisons of longer versus shorter durations of polychemotherapy did not indicate any survival advantage with the use of more than about 3-6 months of polychemotherapy. By contrast, directly randomised comparisons did suggest that, compared with CMF alone, the anthracycline-containing regimens studied produced somewhat greater effects on recurrence (2p=0.006) and mortality (69% vs 72% 5-year survival; log-rank 2p=0.02). But this comparison is one of many that could have been selected for emphasis, the 99% CI reaches zero, and the results of several of the relevant trials are not yet available.
Interpretation: Some months of adjuvant polychemotherapy (eg, with CMF or an anthracycline-containing regimen) typically produces an absolute improvement of about 7-11% in 10-year survival for women aged under 50 at presentation with early breast cancer, and of about 2-3% for those aged 50-69 (unless their prognosis is likely to be extremely good even without such treatment). Treatment decisions involve consideration not only of improvements in cancer recurrence and survival but also of adverse side-effects of treatment, and this report makes no recommendations as to who should or should not be treated.
Comment in
- Polychemotherapy for early breast cancer.
Baum M. Baum M. Lancet. 1998 Nov 7;352(9139):1554. doi: 10.1016/S0140-6736(05)60364-9. Lancet. 1998. PMID: 9820329 No abstract available. - Subsets within the chemotherapy overview. International Breast Cancer Study Group.
Coates AS, Gelber RD, Goldhirsch A. Coates AS, et al. Lancet. 1998 Nov 28;352(9142):1783-4. doi: 10.1016/s0140-6736(05)79861-5. Lancet. 1998. PMID: 9848379 No abstract available. - Sentinel lymph node in breast cancer.
Benson JR, Querci della Rovere G. Benson JR, et al. Lancet. 1999 Dec 4;354(9194):1998; author reply 1999. doi: 10.1016/s0140-6736(05)76770-2. Lancet. 1999. PMID: 10622323 No abstract available.
Similar articles
- Multi-agent chemotherapy for early breast cancer.
Early Breast Cancer Trialists' Collaborative Group. Early Breast Cancer Trialists' Collaborative Group. Cochrane Database Syst Rev. 2002;(1):CD000487. doi: 10.1002/14651858.CD000487. Cochrane Database Syst Rev. 2002. PMID: 11869577 Updated. Review. - WITHDRAWN: Multi-agent chemotherapy for early breast cancer.
Clarke MJ. Clarke MJ. Cochrane Database Syst Rev. 2008 Oct 8;2008(4):CD000487. doi: 10.1002/14651858.CD000487.pub2. Cochrane Database Syst Rev. 2008. PMID: 18843612 Free PMC article. Review. - Tamoxifen for early breast cancer.
Early Breast Cancer Trialists' Collaborative Group. Early Breast Cancer Trialists' Collaborative Group. Cochrane Database Syst Rev. 2001;(1):CD000486. doi: 10.1002/14651858.CD000486. Cochrane Database Syst Rev. 2001. PMID: 11279694 Updated. Review. - Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet. 2005 May 14-20;365(9472):1687-717. doi: 10.1016/S0140-6736(05)66544-0. Lancet. 2005. PMID: 15894097
Cited by
- TP53 signature predicts pathological complete response after neoadjuvant chemotherapy for breast cancer: Observational and confirmational study using prospective study cohorts.
Takahashi S, Sato N, Kaneko K, Masuda N, Kawai M, Hirakawa H, Nomizu T, Iwata H, Ueda A, Ishikawa T, Bando H, Inoue Y, Ueno T, Ohno S, Kubo M, Yamauchi H, Okamoto M, Tokunaga E, Kamigaki S, Aogi K, Komatsu H, Kitada M, Uemoto Y, Toyama T, Yamamoto Y, Yamashita T, Yanagawa T, Yamashita H, Matsumoto Y, Toi M, Miyashita M, Ishida T, Fujishima F, Sato S, Yamaguchi T, Takahashi F, Ishioka C. Takahashi S, et al. Transl Oncol. 2024 Oct;48:102060. doi: 10.1016/j.tranon.2024.102060. Epub 2024 Jul 24. Transl Oncol. 2024. PMID: 39047382 Free PMC article. - Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2-positive early breast cancer: A meta-regression analysis.
Yang MH, Huang CS, Chang DY, Hu FC, Huang SM, Huang PH, Chen IC, Chen TW, Lin CH, Lu YS. Yang MH, et al. Cancer Med. 2024 Jul;13(14):e70005. doi: 10.1002/cam4.70005. Cancer Med. 2024. PMID: 39046067 Free PMC article. - Validation of the RSClin risk calculator in the National Cancer Data Base.
Vannier AGL, Dhungana A, Zhao F, Chen N, Shubeck S, Hahn OM, Nanda R, Jaskowiak NT, Fleming GF, Olopade OI, Pearson AT, Huo D, Howard FM. Vannier AGL, et al. Cancer. 2024 Apr 15;130(8):1210-1220. doi: 10.1002/cncr.35163. Epub 2023 Dec 26. Cancer. 2024. PMID: 38146744 - Consensus guidelines for the management of HR-positive HER2/neu negative early breast cancer in India, SAARC region and other LMIC by DELPHI survey method.
Parikh P, Babu G, Singh R, Krishna V, Bhatt A, Bansal I, Rajappa S, Sahoo TP, Aggarwal S, Bapna A, Biswas G, Somashekhar SP, Bajpai J, Maniar V, Desai S, Raja T, Rath GK. Parikh P, et al. BMC Cancer. 2023 Jul 31;23(1):714. doi: 10.1186/s12885-023-11121-9. BMC Cancer. 2023. PMID: 37525142 Free PMC article. - Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Electronic address: bc.overview@ctsu.ox.ac.uk; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Electronic address: bc.overview@ctsu.ox.ac.uk, et al. Lancet. 2023 Apr 15;401(10384):1277-1292. doi: 10.1016/S0140-6736(23)00285-4. Lancet. 2023. PMID: 37061269 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical